- Home
- CAN vs ERAS Comparison
CAN vs ERAS Comparison
Compare CAN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- ERAS
- Stock Information
- Founded
- CAN 2013
- ERAS 2018
- Country
- CAN Singapore
- ERAS United States
- Employees
- CAN N/A
- ERAS N/A
- Industry
- CAN Semiconductors
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CAN Technology
- ERAS Health Care
- Exchange
- CAN Nasdaq
- ERAS Nasdaq
- Market Cap
- CAN 384.3M
- ERAS 396.6M
- IPO Year
- CAN 2019
- ERAS 2021
- Fundamental
- Price
- CAN $0.75
- ERAS $1.39
- Analyst Decision
- CAN Strong Buy
- ERAS Strong Buy
- Analyst Count
- CAN 5
- ERAS 6
- Target Price
- CAN $3.70
- ERAS $4.83
- AVG Volume (30 Days)
- CAN 20.6M
- ERAS 1.4M
- Earning Date
- CAN 05-20-2025
- ERAS 05-20-2025
- Dividend Yield
- CAN N/A
- ERAS N/A
- EPS Growth
- CAN N/A
- ERAS N/A
- EPS
- CAN N/A
- ERAS N/A
- Revenue
- CAN $269,324,000.00
- ERAS N/A
- Revenue This Year
- CAN $161.88
- ERAS N/A
- Revenue Next Year
- CAN $35.55
- ERAS N/A
- P/E Ratio
- CAN N/A
- ERAS N/A
- Revenue Growth
- CAN 27.35
- ERAS N/A
- 52 Week Low
- CAN $0.54
- ERAS $1.01
- 52 Week High
- CAN $3.27
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- CAN 48.16
- ERAS 51.46
- Support Level
- CAN $0.54
- ERAS $1.37
- Resistance Level
- CAN $0.84
- ERAS $1.61
- Average True Range (ATR)
- CAN 0.07
- ERAS 0.14
- MACD
- CAN 0.01
- ERAS 0.00
- Stochastic Oscillator
- CAN 70.03
- ERAS 45.68
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.